Enveda raises $311 million to advance AI-discovered natural-molecule drugs
The AMW Read
The round confirms an already reported financing event, while the size of the raise and the clinical-stage pipeline make its outcome meaningful for AI-driven drug discovery.
Enveda raises $311 million to advance AI-discovered natural-molecule drugs
Enveda raised $311 million in a Series E led by Catalio Capital Management, bringing its cumulative funding above $845 million. New investors include ICONIQ, Lightspeed, Durable Capital Partners and an unnamed sovereign wealth fund. The US biotech uses its PRISM platform to analyze mass-spectrometry data from natural samples, infer molecular structures and guide experiments that assess potential drug candidates. Chemists then optimize selected molecules for oral use.
The financing backs a drug-discovery approach built around identifying compounds that already exist in nature, rather than designing every candidate from scratch. Enveda says PRISM turns complex sample data into a ranked set of molecules for laboratory work. Its pipeline has reached human testing: ENV-294 has begun Phase 2 trials for atopic dermatitis and asthma, while ENV-308 and the inflammatory bowel disease candidate ENV-6946 have entered Phase 1 studies. That progression matters for AI-driven biotech because a platform's ability to find candidates is only one step toward establishing whether those candidates work in patients.
For investors, the next evidence to watch is clinical data, particularly from ENV-294's two Phase 2 indications. Those results can test the connection between Enveda's discovery process and therapeutic outcomes more directly than the size of this round can. For builders pursuing AI-assisted drug discovery, Enveda's workflow also shows where software meets laboratory execution: mass-spectrometry interpretation helps prioritize molecules, but experiments, chemical optimization and clinical trials still determine which candidates can advance.